{"slideshow_credits": null, "snippet": "A promising new class of cholesterol-lowering drugs known as PCSK9 inhibitors is being developed.", "abstract": "New guidelines governing use of cholesterol-lowering medicines represent huge change for doctors and a vast number of patients, but impact on drug industry is expected to be less tumultuous, largely due to relatively unprofitable status of generic statin drugs; changes do cast into doubt future of new class of cholesterol-lowering drugs known as PCSK9 inhibitors, which had been highly anticipated on Wall Street.", "section_name": "Business Day", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Katie", "role": "reported", "lastname": "THOMAS", "rank": 1, "organization": ""}], "original": "By KATIE THOMAS", "contributor": "Andrew Pollack contributed reporting."}, "web_url": "http://www.nytimes.com/2013/11/15/business/questions-for-a-new-class-of-cholesterol-drugs.html", "lead_paragraph": "A promising new class of cholesterol-lowering drugs known as PCSK9 inhibitors is being developed.", "headline": {"main": "Questions for a New Class of Cholesterol Drugs", "print_headline": "Questions for a New Class of Cholesterol Drugs"}, "_id": "52858c0638f0d830163edc5b", "word_count": "862", "multimedia": [{"height": 126, "url": "images/2013/11/15/business/SubPharma/SubPharma-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2013/11/15/business/SubPharma/SubPharma-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 410, "url": "images/2013/11/15/business/SubPharma/SubPharma-articleLarge.jpg", "legacy": {"xlarge": "images/2013/11/15/business/SubPharma/SubPharma-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "410"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2013/11/15/business/SubPharma/SubPharma-thumbStandard.jpg", "legacy": {"thumbnail": "images/2013/11/15/business/SubPharma/SubPharma-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2013-11-15T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Cholesterol", "name": "subject", "is_major": "Y", "rank": "11"}, {"value": "Regeneron Pharmaceuticals Inc", "name": "organizations", "is_major": "N", "rank": "5"}, {"value": "Zetia (Drug)", "name": "subject", "is_major": "N", "rank": "8"}, {"value": "AstraZeneca PLC", "name": "organizations", "is_major": "N", "rank": "10"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "1"}, {"value": "Heart", "name": "subject", "is_major": "Y", "rank": "12"}, {"value": "Generic Brands and Products", "name": "subject", "is_major": "Y", "rank": "4"}, {"value": "Vytorin (Drug)", "name": "subject", "is_major": "N", "rank": "7"}, {"value": "Statins (Cholesterol-Lowering Drugs)", "name": "subject", "is_major": "Y", "rank": "2"}, {"value": "Crestor (Drug)", "name": "subject", "is_major": "N", "rank": "6"}, {"value": "Merck & Company Inc", "name": "organizations", "is_major": "N", "rank": "9"}], "blog": [], "subsection_name": null, "type_of_material": "News"}